Join
Live feed
·
PRReleasevia Quantisnow
Navidea Biopharmaceuticals Inc. logo

Navidea Biopharmaceuticals Announces Positive Preliminary Results of Its Ongoing Phase 2B Study Comparing Tc99m Tilmanocept Imaging with Histopathology of Joints from Patients with Rheumatoid Arthritis

ByQuantisnow·Wall Street's wire, on your screen.
NAVB· Navidea Biopharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NAVB (Navidea Biopharmaceuticals Inc.) and more on Quantisnow.